The AUC of ATRX for predicting the 3-year OS (AUC =0.842, P = 0.042) and the 5-year OS (AUC =0.848, P = 0.021) of the HER2-/HR+ BC patients who underwent endocrinotherapy were ideal (Supplementary Figure 4A). The gene discussed is ERBB2; the disease is breast cancer.